BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar Sells 31,543 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar sold 31,543 shares of the firm’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $36.14, for a total transaction of $1,139,964.02. Following the transaction, the chief executive officer now owns 211,718 shares of the company’s stock, valued at approximately $7,651,488.52. This represents a 12.97 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Neil Kumar also recently made the following trade(s):

• On Tuesday, January 28th, Neil Kumar sold 326,932 shares of BridgeBio Pharma stock. The stock was sold at an average price of $36.29, for a total value of $11,864,362.28.

BridgeBio Pharma Stock Performance

NASDAQ BBIO opened at $36.29 on Thursday. The stock has a market capitalization of $6.86 billion, a P/E ratio of -15.06 and a beta of 1.07. BridgeBio Pharma, Inc. has a 52 week low of $21.62 and a 52 week high of $37.81. The stock has a fifty day moving average of $31.53 and a 200-day moving average of $27.79.

Institutional Trading of BridgeBio Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Polar Asset Management Partners Inc. bought a new position in shares of BridgeBio Pharma in the 3rd quarter valued at about $1,286,000. First Turn Management LLC bought a new position in BridgeBio Pharma in the third quarter valued at approximately $10,178,000. Janus Henderson Group PLC grew its holdings in BridgeBio Pharma by 11.7% during the 3rd quarter. Janus Henderson Group PLC now owns 4,818,012 shares of the company’s stock worth $122,658,000 after acquiring an additional 505,481 shares during the period. Intech Investment Management LLC bought a new stake in shares of BridgeBio Pharma during the 3rd quarter valued at $1,136,000. Finally, Principal Financial Group Inc. lifted its stake in shares of BridgeBio Pharma by 1.8% in the 3rd quarter. Principal Financial Group Inc. now owns 1,145,123 shares of the company’s stock valued at $29,155,000 after purchasing an additional 19,978 shares during the period. 99.85% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Bank of America upped their price target on BridgeBio Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, November 25th. HC Wainwright reiterated a “buy” rating and set a $49.00 target price on shares of BridgeBio Pharma in a research report on Thursday, February 13th. Evercore ISI lifted their price target on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a report on Monday, December 23rd. Finally, Scotiabank upped their price objective on shares of BridgeBio Pharma from $48.00 to $49.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, February 12th. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $49.08.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.